Relay Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $24.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $20.52M.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $3.67M.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$6.53M.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$507.00K, a 144.36% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$11.44M, a 211.41% decline from fiscal 2024.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $10.27M.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$9.59M, a 184.95% decline from fiscal 2022.
- Relay Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $11.29M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $24.19M 10-Q · filed 2026-08-06 | $17.65M derived: sum of 3 quarters · filed 2026-08-06 | $17.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.67M 10-Q · filed 2026-05-05 | -$2.87M derived: sum of 2 quarters · filed 2026-05-05 | -$3.38M derived: sum of 3 quarters · filed 2026-05-05 | -$4.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$7.04M derived: sum of 2 quarters · filed 2026-02-26 | -$7.99M derived: sum of 3 quarters · filed 2026-08-06 | -$11.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$507.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.46M derived: sum of 2 quarters · filed 2026-08-06 | -$4.91M 10-Q · filed 2025-11-06 | -$12.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$953.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.40M 10-Q · filed 2026-08-06 | -$11.69M derived: sum of 3 quarters · filed 2026-08-06 | -$10.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$3.45M 10-Q · filed 2026-05-05 | -$10.74M derived: sum of 2 quarters · filed 2026-05-05 | -$9.60M derived: sum of 3 quarters · filed 2026-05-05 | -$823.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.15M derived: sum of 2 quarters · filed 2026-02-26 | $2.62M derived: sum of 3 quarters · filed 2026-02-26 | $10.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.92M derived: sum of 2 quarters · filed 2025-11-06 | $17.56M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $8.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $16.42M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $7.64M 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | -$9.59M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $11.29M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |